Expression of binding of plasminogen, thrombospondin, vitronectin, and fibrinogen, and adhesive properties by *Escherichia coli* strains isolated from patients with colonic diseases

W Shen, H Steinrück, Å Ljungh

Abstract

Escherichia coli strains isolated from patients with colonic disorders (n=27) and strains isolated from the rectal mucosa of healthy subjects (n=24) were compared with respect to expression of cell surface hydrophobicity, carriage of intestinal virulence factors, adhesion to tissue culture cells, and expression of binding of extracellular matrix proteins and plasma proteins. Strains isolated from patients with colonic disease did not express a more hydrophobic cell surface than strains from healthy subjects. Few strains from both groups carried genes encoding for recognised virulence factors of *E. coli*. Only one strain, carrying the *eae* gene induced actin polymerisation in tissue culture cells. Strains from patients with colonic diseases adhered to HT29 cells, which are of intestinal origin, to a higher extent than *E. coli* from healthy subjects. Significantly more strains from patients with colonic disorders than *E. coli* from healthy subjects expressed binding of fibronectin, collagens, laminin, vitronectin, plasminogen, thrombospondin, and fibrinogen. Expression of binding of these proteins may influence the pathogenesis of colonic disease by mediating binding to ulcerated tissue, preventing complement induced lysis of bacteria and by exerting proteolytic activity. There was no correlation between serotype, expression of cell surface hydrophobicity, and binding of extracellular matrix and plasma proteins. (Gut 1995; 36: 401-406)

Keywords: *E. coli*, colonic disease, protein binding expression, adhesive properties.

Ulcerative colitis is a chronic, relapsing disease usually affecting the distal colon. The aetiology of the disease and causes of exacerbations are still unknown. Because of the resemblance to infectious colitis, several attempts have been made to link a microbial agent to ulcerative colitis, such as the invasive organisms *Shigella* sp, *Salmonella* sp, and *Campylobacter jejuni*.¹ Also toxin producing bacteria such as *Clostridium difficile* have been isolated in connection with relapse of ulcerative colitis.² Shiga like toxin (Vero toxin) producing *Escherichia coli* were isolated from some patients during relapse and may have aggravated the symptoms³⁻⁷ but shiga like toxin producing *E. coli* were not more

frequently isolated from rectal biopsy specimens of patients with ulcerative colitis than from healthy subjects.^{4,8} No bacterial species has been linked conclusively to the disease.

One hydrophobic adhesin mediating adhesion to buccal cells was described by Burke and Axon.⁹ In contrast, strains isolated from rectal biopsy specimens of patients with ulcerative colitis did not express higher cell surface hydrophobicity than strains isolated from the rectal mucosa of healthy subjects.⁶

A number of virulence factors have been described in *E. coli* causing infection of the small intestine, such as enterotoxins, fimbrial adhesins, and outer membrane proteins of non-fimbrial nature.¹⁰ Very few virulence factors of *E. coli* causing colitis have been characterised. Apart from the classic enteroinvasive *E. coli*, where the invasive ability is conferred by a 140 kDa plasmid, enteropathogenic *E. coli* strains have been shown to possess invasive ability.¹¹⁻¹³ Interestingly, immotile, shigella like *E. coli* were more commonly isolated from patients than from healthy subjects, though the difference was not statistically significant.^{6,14} Whether these strains have invasive properties is under investigation.

We have previously shown that strains from patients with ulcerative colitis commonly express binding of fibronectin, collagen type I, and laminin.^{4,6,7} These extracellular matrix proteins are certainly exposed in colonic ulcers during a relapse of ulcerative colitis, and expression of binding of these proteins could represent a mechanism for anchoring bacteria in the tissue. Whether these proteins are also exposed in non-ulcerated colonic mucosa has not been elucidated. The link protein of colonic mucus was proposed to be an Fn fragment but this has not been confirmed.¹⁵

This study was undertaken to analyse expression of binding of vitronectin, plasminogen, thrombospondin, and fibrinogen by *E. coli* strains isolated from rectal biopsy specimens of patients with ulcerative colitis and other colonic diseases and healthy subjects, and to further investigate adhesive properties of these strains.

Methods

BACTERIAL STRAINS

E. coli strains isolated as the dominating strain from rectal biopsy specimens of patients with relapse of ulcerative colitis (n=20), Crohn's disease (n=2), colitis and proctitis of unknown

Department of
Medical Microbiology,
University of Lund,
Lund, Sweden
W Shen
Å Ljungh

Robert Koch-Institut,
Berlin, Germany
H Steinrück

Correspondence to:
Associate Professor Å
Ljungh, Department of
Medical Microbiology,
Sölvegatan 23, S-223 62
Lund, Sweden.

Accepted for publication
9 June 1994

cause ($n=5$), and from rectal mucosa of healthy subjects ($n=24$) were studied. The strains were serotyped according to Örskov and Örskov.¹⁶ *E coli* E2348 was used as control in phalloidin staining. Strains were stored in tryptic soy broth with glycerol (20% w/v) at -80°C . Unless otherwise stated strains were cultured on colonisation factor agar at 37°C overnight.¹⁷

CELL SURFACE HYDROPHOBICITY

The cell surface hydrophobicity was determined by the salt aggregation test as earlier described.¹⁸ The highest dilution of ammonium sulphate (final concentration) in which visible aggregation occurred is the salt aggregation test value.

PROTEIN BINDING

Vitronectin, fibrinogen, thrombospondin, plasminogen (Glu-Plg and Lys-Plg), fibronectin, collagen type I and IV, and laminin were radiolabelled with Iodobeads¹⁹ to a specific activity of around 4×10^6 cpm/ μg protein. One hundred μl of washed bacterial cells (7×10^7) in phosphate buffered saline (0.02 M sodium phosphate buffer, pH 6.8 in 0.15 M NaCl) was mixed with 100 μl (about 25 000 cpm) of ^{125}I -labelled protein in phosphate buffered saline. Measurement of expression of binding was performed as previously described.^{20, 21} Results are expressed as mean values of duplicate samples, and represent amount of bound protein in percentage of total amount of added labelled protein. Less than 10% binding is considered negative, 10–15% binding low, 15–40% binding moderate, and >40% binding as high binding. *E coli* NG7C was included as positive control and strain PSS1 as negative control.²⁰

HYBRIDISATION

Colony blot hybridisation was performed with genes encoding for attachment effacing (eae) and enteropathogenic *E coli* adherence factor, (EAF), and synthetic oligonucleotides for heat labile and heat stable enterotoxins, shiga like toxin I and II, and enteroinvasivity (the 140 kDa plasmid).²² Hybridisation was performed under stringent conditions.

ADHESION TESTS

Strains were tested for adhesion to HT29 and HeLa cells according to Cravioto *et al.*²³ Subconfluent monolayers of tissue culture cells on 13 mm diameter glass cover slips were placed in multiwell tissue culture plates with 1 ml HEPES buffered minimal essential medium with 5% fetal calf serum and 0.5% D-mannose. Ten μl of an overnight colonisation factor broth culture of bacterial strains was added to each well and incubated for three hours at 37°C in 5% carbon dioxide. The cover slips were washed three times in phosphate buffered saline and fixed for 20 minutes in 3% formalin. The number of adhering bacteria to

at least 200 cells was counted. The data were expressed as mean values. To study the effect on the cytoskeleton, strains were incubated with HEP-2 cells and HT29 cells and stained with phalloidin as described by Knutton *et al.*²⁴

CHEMICALS

Vitronectin was purified according to Yatohgo *et al.*²⁵ and fibronectin according to Vuento and Vaheri.²⁶ Lys-plasminogen and glu-plasminogen were gifts from Dr U Hedner, Novo AS, Copenhagen, Denmark, thrombospondin from Dr J Lawler, Boston, USA, and laminin from Dr K H Valkonen, University of Oulu, Oulu, Finland. Collagen type I was purchased from Collagen Research, Palo Alto, CA, USA, and collagen type IV from Heyl AG, Germany. Agar bases were purchased from LabM, Salford, United Kingdom, fibrinogen from KABI-Pharmacia, Uppsala, Sweden, Iodobeads from Amersham International, Amersham, United Kingdom, phalloidin, Tween 20 and bovine serum albumin from Sigma Chemical, St Louis, MO, USA, and gentamicin from Schering Plough, Kenilworth, NJ, USA, tryptic soy broth was from Difco Laboratories, Detroit, MI. Salts were from Merck AG, Darmstadt, Germany. Tissue culture media were from Flow Laboratories, Rickmansworth, United Kingdom. All chemicals were of analytical grade.

STATISTICAL ANALYSES

The Mann-Whitney unpaired non-parametric test was used for statistical analysis.

Results

Most of the strains isolated from healthy subjects expressed moderate cell surface hydrophobicity (salt aggregation test 0.5–1.6, Table I) whereas most of the strains isolated from patients with inflammatory bowel disease or other colonic disorders expressed low surface hydrophobicity (salt aggregation test 2 or >2, Table I).

The strains isolated from patients with colonic disorders expressed binding of the proteins to a high extent and only three strains did not bind any of the proteins (Figure, Table II). There was no significant difference in binding of Lys-plasminogen or Glu-plasminogen. The highest degree of binding was of fibrinogen in that 14 strains expressed high binding, 10 moderate binding, one low binding, and three strains did not bind fibrinogen. The lowest degree of binding was with vitronectin. Two strains from patients with colonic disease expressed high binding, 17 moderate binding, four strains low binding, and five strains did not bind vitronectin. Six strains bound thrombospondin to a high degree, and two strains plasminogen. In contrast, two strains isolated from healthy rectal mucosa expressed high binding of fibrinogen, one of thrombospondin, and 18 strains did not bind any of the proteins tested. The difference in expression of binding between patients with colonic disorders and

TABLE 1 Characteristics of *E. coli* strains

Strain	Diagnosis	Serotype	Hybridisation with probe	CSH*	Adhesion to cells†	
					HeLa	HT29
RL3	UC	ND ³		2	ND	ND
RL4	UC	O8:H-		>2	5	10
RL10	UC	O119:H54		2	17	15
RL36	UC	O143:H4		>2	12	5
RL41	UC	ONT:H27		>2	7	5
RL49	UC	O18:K1:H7		>2	5	5
RL50	UC	O1:H-		2	5	5
RL51	UC	O1:H4	SLTI	>2	100	100
RL64	Crohn's disease	O7:H4	SLTI	>2	35	5
RL65	Proctitis	O7:H4		>2	12	25
RL66	UC	O2:K1:H7	SLTI, eae	2	35	15
RL70	UC	O23:H-		>2	35	15
RL74	UC	O12:H19		1	25	10
RL78	Crohn's disease	ONT:H37	SLTI	2	7	5
RL81	IBD	O7:H4		>2	25	25
RL90	UC	O23:K1:H6	SLTI	2	5	25
RL92	Colitis	O53:H7		>2	12	15
RL96	UC	O7:H15		2	12	10
RL99	UC	O86:K5:H10	SLTI+II	>2	25	25
RL100	UC	ONT:H26	SLTI	>2	12	10
RL109	UC	O23:H16		>2	35	40
RL110	Colitis	ONT:H-		>2	15	15
RL114	UC	O7:H4	SLTII	>2	7	15
RL118	UC	O159:H4		>2	12	15
RL129	Colitis	O2:H-		1	35	25
RL131	Proctitis	O99:H53	SLTI	0.5	35	15
Ec 40	UC	O147:H21		1.6	ND	ND
Ec 44	Healthy	O20		>2	ND	ND
Ec 53	Healthy	O77:H?		>2	7	5
Ec 54	Healthy	O6:H-		0.1	6	8
Ec 71	Healthy	O8:H10		>2	7	15
Ec 76	Healthy	O8:K42		>2	5	10
Ec 80	Healthy	O121		1.6	5	ND
Ec 102	Healthy	O83:H?		0.9	27	15
Ec 107	Healthy	O101:K103:H9		1.6	8	9
Ec 109	Healthy	O7:K1		1.6	7	5
Ec 110	Healthy	O20, 133:H-		1.6	24	23
Ec 111	Healthy	O1:K1:H-		1.6	12	15
Ec 115	Healthy	O2		0.9	5	5
Ec 116	Healthy	O25:H rough		0.1	22	15
Ec 118	Healthy	O50:H5		0.9	25	0
Ec 119	Healthy	O7		>2	17	10
Ec 120	Healthy	O8		<0.1	100	5
Ec 121	Healthy	O154:H4		>2	12	5
Ec 127	Healthy	O18ac, 53		0.9	22	5
Ec 138	Healthy	O2:K51:H7		1.6	100	25
Ec 140	Healthy	O8:K29:H-		>2	12	10
Ec 148	Healthy	O40	SLTI	1.6	17	10
Ec 151	Healthy	O2:H7		1.6	100	10
Ec 152	Healthy	O87:H19		>2	ND	ND
Ec194	Healthy	O112ab		1.6	18	10

*CSH=cell surface hydrophobicity as determined by salt aggregation test. †Number of bacterial cells/tissue culture cell. ND=not done; IBD=inflammatory bowel disease; UC=ulcerative colitis.

healthy persons was highly significant ($p < 0.001$).

Also, binding of fibronectin, collagen type I and IV, and laminin was more common among strains isolated from patients with colonic disorders than from healthy subjects ($p < 0.001$) (Figure, Table II). Although several strains expressed binding of more than one protein, and some strains did not bind any protein, expression of binding of the different extracellular matrix proteins and fibrinogen does not seem to be coregulated.

There was no correlation between either serotype or cell surface hydrophobicity and binding of the different proteins. The number of patients in the ulcerative colitis group was too small to permit correlations between expression of protein binding and activity of disease.

One strain isolated from a patient with ulcerative colitis adhered at high numbers (100 bacteria/cell) to HT29 as well as to HeLa cells, and three strains from healthy subjects adhered at high numbers to HeLa cells but not to HT29 cells (Table I). There was a poor correlation between adhesion to HeLa and HT29 cells. Strains from ulcerative colitis patients, however, adhered at significantly higher

numbers per cell to HT29 cells than strains from healthy subjects ($p = 0.0199$). There was no correlation between expression of cell surface hydrophobicity and adhesion to either tissue culture cell line. Nor was there any correlation between serotype and adhesion to the cell lines.

Thirteen strains were stained with phalloidin after incubation with HEp 2 and HT29 cells. Only strain RL66, which hybridises with probes for eae and SLTII gave the typical accumulation of actin in HEp-2 cells. The staining of HT29 cells was less pronounced but all strains except one induced changes in the cells. After incubation with one strain of serotype O50, all cells were lysed. A typical finding was that there were no normal actin filament bundles in the cells.

No strain hybridised with the established *E. coli* virulence factors: heat labile or heat stable enterotoxins, invasivity plasmid or enteropathogenic *E. coli* adherence factor. One strain hybridised with eae, and seven strains isolated from patients with colonic illness with SLTI (Table I). One strain hybridised with the SLTII probe, and one strain with both SLTI and SLTII probes. One of the strains isolated from healthy rectal mucosa hybridised with the SLTI probe.

Discussion

Twenty years ago Cooke *et al.*²⁷ tried to link virulence properties of *E. coli* to the precipitation of relapse of ulcerative colitis. We subsequently described the isolation of shiga like toxin producing *E. coli* in patients with relapse of ulcerative colitis.^{3,7} This was later confirmed by others.⁵ In a study on the cause of infections and non-infectious colitis, the incidence of shiga like toxin producing *E. coli* was similar among strains isolated from rectal biopsy specimens of patients with a first episode of ulcerative colitis and with infectious colitis.²⁸ In the same study very few strains were shown to carry the hitherto described virulence factors of *E. coli*.²⁸ This was to be expected as most of these virulence factors play a part in infections of the small intestine. Interestingly, enteropathogenic *E. coli* adherence factor and attachment effacement factor (eae) have been described to act both in the small and large intestine.²⁹ In our study, only one strain from a patient with ulcerative colitis carried the eae gene, which shows that neither of these virulence factors are common in strains isolated from patients with inflammatory bowel disease. Our data, however, support the finding by Knutton *et al.* that strains carrying eae induce actin accumulation in intestinal cells from both the small and large intestine.²⁴

We have further found that *E. coli* strains producing haemolysin but not colicin were more commonly isolated from biopsy specimens of patients with ulcerative colitis than patients with infectious colitis.¹⁴ These strains may be similar to virulent *Salmonella* strains.³⁰ The pathogenesis of ulcerative colitis and relapse of ulcerative colitis is probably multifactorial, but a subset of *E. coli* strains adhering

Number of *E. coli* strains isolated from patients with colonic disorders and healthy subjects expressing binding of vitronectin, fibrinogen, Glu-plasminogen, thrombospondin, fibronectin, collagen type I, and laminin.

to colonic mucosa may express virulence determinants, which may aggravate a relapse of inflammatory bowel disease. Adhesion to epithelial cells can be mediated by receptor specific interactions, hydrophobic or charge interactions. Strains isolated from the stools of patients with ulcerative colitis were reported to carry a hydrophobic surface protein mediating adhesion to buccal cells.⁹ *E. coli* strains isolated from the stools of patients with ulcerative colitis and Crohn's disease also adhered to buccal cells to a significantly greater extent than strains isolated from normal controls.⁸ In contrast, we reported that strains isolated from the rectal mucosa of healthy subjects expressed high cell surface hydrophobicity to a larger

extent than strains isolated from rectal biopsy specimens of patients with ulcerative colitis.⁶ The data in this study confirm our earlier findings.

Although only one of the strains isolated from patients with colonic diseases adhered to a great extent (100 bacterial cells/tissue culture cell) to HT29 cells and HeLa cells, and three strains from healthy subjects adhered to HeLa cells in high numbers, strains isolated from patients with colonic disorders adhered in significantly higher numbers to HT29 cells than strains from healthy subjects (Table I). HeLa cells are not of intestinal origin and HT29 cells are malignant intestinal cells, which may express surface structures differing from those of patients with ulcerative colitis as well as of healthy subjects. Similarly, the adhesion to buccal cells of strains isolated from patients with ulcerative colitis may not be relevant for adhesion to cells from the large intestine.^{8,9} The data on adhesiveness presented here, however, could show that adhesion plays a part in pathogenesis. This should be explored using colonic cells, preferably from patients with colonic disorders as well as from healthy subjects.

We have earlier shown that *E. coli* strains of intestinal and extraintestinal origin commonly bind fibronectin, collagen, and vitronectin.²⁰ In a study of *E. coli* strains isolated from patients with ulcerative colitis and other colonic disorders most strains expressed binding of fibronectin, collagen, or laminin, or all three.⁴ The data in this study support these findings. In this study *E. coli* strains were further analysed for expression of binding of vitronectin, fibrinogen, thrombospondin, and plasminogen. Strains isolated from patients with colonic disorders expressed binding of

TABLE II Binding of fibronectin, collagen type I and IV, laminin, vitronectin, fibrinogen, thrombospondin, and plasminogen by selected *E. coli* isolated from patients with ulcerative colitis and healthy subjects

Percentage binding of									
Strain	Fibronectin	Collagen type I	Collagen type II	Laminin	Vitronectin	Fibrinogen	Thrombospondin	Lys-plasminogen	Glu-plasminogen
RL4	70	78	70	60	3	4	3	5	7
RL10	76	76	76	73	50	80	60	45	37
RL36	19	20	24	23	8	23	9	6	10
RL41	14	33	34	31	23	47	46	34	33
RL49	54	46	52	36	19	58	37	28	26
RL50	50	44	16	16	1	3	4	2	5
RL66	55	60	43	43	14	64	16	11	12
RL74	18	26	20	18	11	30	4	5	7
RL78	29	35	23	23	12	41	47	33	30
RL81	37	39	49	33	12	25	13	6	10
RL90	53	64	49	44	16	69	3	4	5
RL96	39	51	41	25	17	30	38	13	15
RL99	32	48	28	35	14	47	18	7	9
RL100	54	43	43	34	13	39	35	14	15
RL109	14	32	24	16	10	23	17	12	8
RL110	13	30	25	28	11	44	10	8	10
RL118	44	46	35	29	10	50	50	28	25
RL129	3	2	3	9	49	63	73	51	40
Ec 40	7	8	6	<2	<2	2	3	2	3
Ec 53	22	4	2	ND	13	12	30	12	13
Ec 76	<2	<2	<2	3	2	<2	<2	<2	2
Ec 80	<2	<2	<2	3	<2	3	2	<2	2
Ec 107	<2	<2	<2	<2	<2	<2	<2	<2	<2
Ec 115	<2	<2	<2	<2	3	9	9	8	9
Ec 116	<2	<2	<2	<2	6	10	17	9	13
Ec 118	<2	<2	<2	ND	24	55	52	34	30
Ec 127	<2	<2	<2	ND	5	18	18	10	14
Ec 148	8	23	19	ND	<2	4	4	2	5
Ec 151	36	41	36	ND	15	41	38	22	22
Ec 152	7	23	19	ND	5	<2	<2	3	3
Ec 194	3	17	12	12	3	<2	3	5	6

ND=not done. >40% binding denotes high binding, 15–40% moderate binding, and 10–15% low binding.

these proteins to a significantly higher extent than strains from healthy persons (Figure, Table II). This may be of relevance in the pathogenesis in different ways. Fibrinogen binding by *Staphylococcus aureus* is well known to induce fibrin formation and abscesses. Furthermore, fibrin is exposed in intestinal ulcers, hence expression of fibrinogen binding may mediate binding of *E. coli* to ulcers. Fibrinogen is a 'sticky' protein and the reported binding may not be caused by receptor specific interaction. The pathogenetic effects of binding, however – that is, transformation of fibrinogen to fibrin and adhesion to fibrin in ulcerated mucosa – will probably occur regardless of the character of the binding.

Vitronectin binds to complement factors C5–9 and inhibits polymerisation of C9.³¹ Whether vitronectin binding by bacteria interferes with this process has not been elucidated. Binding of vitronectin and other extracellular matrix proteins may represent a mechanism of protection from complement induced cell lysis, as earlier proposed for non-specific immunoglobulin binding to protein A of *S. aureus*,³² and hence enhance survival in tissues.

Plasminogen binding of *S. aureus* and streptococci has been described earlier.^{33,34} When Glu-plasminogen is bound to a bacterial surface it is converted to plasmin. In this form, it is protected from inactivation by inhibitors in plasma and may thus continue to exert proteolytic activity. Glu-plasminogen is more active than Lys-plasminogen. In the study by Ullberg *et al.*,³⁵ *E. coli* strains of non-intestinal origin did not express plasminogen binding. It is thus very interesting that most strains isolated from patients with colonic diseases expressed plasminogen binding. *E. coli* strains carrying S-fimbriae have been shown to form a complex with plasminogen, generating bacteria bound plasmin, which promoted bacterial invasion and contributed to systemic activation of fibrinolysis.³⁶ If *E. coli* bind plasminogen also in the colonic epithelium and similar effects are obtained, proteolytic activity, which enhances epithelial invasion or fibrinolytic activity, or both should be explored.

Thrombospondin is an important platelet glycoprotein and also forms part of the extracellular matrix in response to inflammation and injury. *S. aureus* strains have earlier been shown to express binding of thrombospondin,³⁷ and this was postulated to mediate adhesion of staphylococcal cells to surfaces. Microthrombi were shown to be prevalent in intestinal biopsy specimens of patients with ulcerative colitis.³⁸ Binding of thrombospondin may well interfere with platelet activation and formation of microthrombi, and also represent a mechanism of tissue adherence. This should be further explored in the pathogenesis of ulcerative colitis.

Expression of fibronectin binding by *E. coli* is enhanced in the presence of calcium ions and suppressed in the presence of increased salt concentration, and the growth medium influences expression of collagen, vitronectin, and laminin also.²¹ Whether or not the growth

environment in the colonic epithelium enhances expression of extracellular matrix binding properties has not been studied. In this study, we show that strains isolated from patients with colonic disease have the ability to express binding of several extracellular matrix proteins and fibrinogen expression of binding of these proteins may enhance adhesion to colonic mucosa and contribute to tissue damage.

This study was supported by grants from the Swedish Medical Research Council (16x-09929), the Nanna Svartz Foundation, and the Royal Physiographic Society, Lund, Sweden. We gratefully acknowledge the kind gifts of plasminogen, thrombospondin, and laminin, as well as of oligonucleotides for enterotoxins and shiga like toxin I and II from Dr Ö Olsvik, CDC, Atlanta, GA, USA, and *E. coli* E2348 from Dr S Knutton, University of Birmingham, Birmingham, United Kingdom.

- 1 Ljungh Å. Microbiological aspects of inflammatory bowel disease. In Järnerot G, Lennard-Jones J, Truelove S, eds. *Inflammatory bowel disease*. Malmö: Corona Press, 1992: 73–89.
- 2 Meyers S, Mayer L, Bottone E, Desmond E, Janowitz H. Occurrence of *Clostridium difficile* toxin during the course of inflammatory bowel disease. *Gastroenterology* 1981; **80**: 697–700.
- 3 Ljungh Å, Eriksson M, Eriksson Ö, Henter J-I, Wadström T. Shiga-like toxin production and connective tissue protein binding of *Escherichia coli* isolated from a patient with ulcerative colitis. *Scand J Infect Dis* 1988; **20**: 443–6.
- 4 Olusanya O, Steinrück H, Aleljung P, Ascencio F, Curman B, Järnerot G, *et al.* Surface properties, connective tissue protein binding and Shiga-like toxin production of *Escherichia coli* isolated from patients with ulcerative colitis. *Int J Med Microbiol* 1992; **276**: 254–63.
- 5 von Wulffen H, Russman H, Karch H. Verocytotoxin-producing *Escherichia coli* O2:H5 isolated from patients with ulcerative colitis. *Lancet* 1988; **i**: 1449–50.
- 6 Ljungh Å, Aleljung P, Malmer C, Selander B, Wadström T. Subepithelial connective-tissue protein binding in *Escherichia coli* isolated from patients with ulcerative colitis and healthy persons. *Microbial Ecology and Therapy* 1993; **21**.
- 7 Ljungh Å, Wadström T. Subepithelial connective tissue protein binding of *Escherichia coli* isolated from patients with ulcerative colitis. In: McDermott RP, ed. *Inflammatory bowel disease: current status and future approach*. Amsterdam: Elsevier Science, 1988: 571–5.
- 8 Gaffer MH, Holdsworth CD, Duerden BI. Virulence properties of *Escherichia coli* isolated from patients with inflammatory bowel disease. *Gut* 1992; **33**: 646–50.
- 9 Burke DA, Axon ATR. Hydrophobic adhesin of *Escherichia coli* in ulcerative colitis. *Gut* 1988; **29**: 41–3.
- 10 Levine MM, Prado V, Robins-Browne R, Lior H, Kaper JB, Moseley SL, *et al.* Use of DNA probes and HEP-2 cell adherence assay to detect diarrheagenic *Escherichia coli*. *J Infect Dis* 1988; **158**: 224–8.
- 11 Donnenberg MS, Donohue-Rolfe A, Keusch GT. Epithelial cell invasion an overlooked property of enteropathogenic *Escherichia coli* associated with the EPEC adherence factor. *J Infect Dis* 1989; **160**: 452–9.
- 12 Andrade JRC, Da Veiga VF, Santa Rosa MR, Suassuna I. An endocytic process in HEP-2 cells induced by enteropathogenic *Escherichia coli*. *J Med Microbiol* 1989; **28**: 49–57.
- 13 Fletcher JN, Embaye HE, Getty B, Batt RM, Hart CA, Saunders JR. Novel invasion determinant of enteropathogenic *Escherichia coli* plasmid pLV501 encodes the ability to invade intestinal epithelial cells and HEP-2 cells. *Infect Immun* 1992; **60**: 2229–36.
- 14 Schumacher G, Steinrück H, Geyid A, Kollberg B, Ljungh Å. Virulence properties of *Escherichia coli* isolated from the rectal mucosa of patients with first attacks of colitis. *Microbial Ecology in Health and Disease* (in press).
- 15 Slomiany A, Okazaki K, Tamura S, Slomiany BL. Identity of mucin's '118-kDa link protein' with fibronectin fragment. *Arch Biochem Biophys* 1991; **286**: 383–8.
- 16 Ørskov F, Ørskov I. Serotyping of *Escherichia coli*. In: Bergan T, Norris JR, eds. *Methods of microbiology*. London: Academic Press, 1978; **14**: 1–77.
- 17 Evans DG, Evans Jr DJ, Tjoa WS, DuPont HL. Detection and characterization of colonization factor of enterotoxigenic *Escherichia coli* isolated from adults with diarrhea. *Infect Immun* 1978; **19**: 727–36.
- 18 Lindahl M, Faris A, Wadström T, Hjertén S. A new test based on 'salting out' to measure relative surface hydrophobicity of bacterial cells. *Biochim Biophys Acta* 1981; **677**: 471–6.
- 19 Markwell MAK. A new solid state reagent to iodinate proteins. *Anal Biochem* 1982; **125**: 427–32.
- 20 Ljungh Å, Emödy L, Steinrück H, Sullivan PB, West B, Zetterberg E, *et al.* Fibronectin, vitronectin and collagen binding to *Escherichia coli* of intestinal and extraintestinal origin. *Int J Med Microbiol* 1990; **274**: 126–34.
- 21 Ljungh Å, Emödy L, Aleljung P, Olusanya O, Wadström T. Growth conditions for the expression of fibronectin, collagen type I, vitronectin and laminin binding to

- Escherichia coli* strain NG7C. *Current Microbiology* 1991; 22: 97-102.
- 22 Wiström J, Gentry LO, Palmgren A-C, Price M, Nord C-E, Ljungh Å, *et al.* Ecological effects of short-term ciprofloxacin treatment of travellers' diarrhoea. *J Antimicrob Chemother* 1992; 30: 693-706.
 - 23 Cravioto A, Tello A, Navarro A, Ruiz J, Villafán H, Uribe F, *et al.* Association of *Escherichia coli* HEp-2 adherence patterns with type and duration of diarrhoea. *Lancet* 1991; 337: 262-4.
 - 24 Knutton S, Baldwin T, Williams PH, McNeish AS. Actin accumulation at sites of bacterial adhesion to tissue culture cells. Basis of a new diagnostic test for enteropathogenic and enterohemorrhagic *Escherichia coli*. *Infect Immun* 1989; 57: 1290-8.
 - 25 Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin for human plasma by heparin affinity chromatography. *Cell Struct Funct* 1988; 13: 281-92.
 - 26 Vuento M, Vaheri A. Purification of fibronectin from plasma by affinity chromatography under non-denaturing conditions. *Biochem J* 1979; 183: 331-7.
 - 27 Cooke EM, Ewins SP, Hywel-Jones J, Lennard-Jones JE. Properties of strains of *Escherichia coli* carried in different phases of ulcerative colitis. *Gut* 1974; 15: 143-6.
 - 28 Schumacher G, Kollberg B, Sandstedt B, Jorup C, Grillner L, Ljungh Å, *et al.* A prospective study of non-relapsing colitis and first attacks of inflammatory bowel disease. *Scand J Gastroenterol* 1993; 28: 1077-85.
 - 29 Yu J, Kaper JB. Cloning and characterization of the *eae* gene of enterohemorrhagic *Escherichia coli* O157:H7. *Mol Microbiol* 1992; 6: 411-7.
 - 30 Gulig PA, Curtiss III R. Plasmid-associated virulence of *Salmonella typhimurium*. *Infect Immun* 1987; 55: 2891-901.
 - 31 Dahlbäck B, Podack ER. Characterization of human S protein, an inhibitor of the membrane attack complex of complement. *Biochem J* 1985; 24: 2368-74.
 - 32 Boyle MDP. *Bacterial immunoglobulin-binding proteins* I. San Diego: Academic Press, 1990.
 - 33 Kuusela P, Saksela O. Binding and activation of plasminogen at the surface of *Staphylococcus aureus*. *Eur J Biochem* 1990; 193: 759-65.
 - 34 Kuusela P, Kaukoranta-Tolvanen S-F, Ullberg M, Kronvall G, Saksela O. Surface associated activation of plasminogen on staphylococci and streptococci, and novel mechanisms for bacteremia to use the activator system of the host. In: Wadström T, Holder IA, Kronvall G, eds. *Molecular pathogenesis of surgical infections*. Stuttgart: Gustav Fischer Verlag (in press).
 - 35 Ullberg M, Kronvall G, Karlsson I, Wiman B. Receptors for human plasminogen on Gram-negative bacteria. *Infect Immun* 1990; 58: 21-5.
 - 36 Parkkinen J, Hacker J, Korhonen TK. Enhancement of tissue plasminogen activator-catalyzed plasminogen activation by *Escherichia coli* S fimbriae associated with neonatal septicemia and meningitis. *Thromb Haemost* 1991; 65: 483-6.
 - 37 Herrman M, Suchard SJ, Boxer LA, Waldvogel FA, Lew PD. Thrombospondin binds to *Staphylococcus aureus* and promotes staphylococcal adherence to surfaces. *Infect Immun* 1991; 59: 279-88.
 - 38 Rose PE, Armour JA, Williams CE, Hill FGH. Verotoxin and neuraminidase induced platelet aggregation activity in plasma: their possible role in the pathogenesis of the haemolytic uraemic syndrome. *J Clin Pathol* 1985; 38: 438-41.